Krystal Biotech Announces Settlement with PeriphaGen, Inc.
15 mars 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding...
Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
28 févr. 2022 07h00 HE
|
Krystal Biotech, Inc.
Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H...
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
24 févr. 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief...
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
18 janv. 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing...
Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
30 nov. 2021 20h15 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the...
Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
29 nov. 2021 16h20 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a...
Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
29 nov. 2021 07h00 HE
|
Krystal Biotech, Inc.
• Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints VYJUVEKTM was well...
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
08 nov. 2021 07h00 HE
|
Krystal Biotech, Inc.
– Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 – Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat...
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
26 oct. 2021 07h00 HE
|
Krystal Biotech, Inc.
Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint...
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis
19 oct. 2021 16h05 HE
|
Krystal Biotech, Inc.
PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of...